



***Prof. Massimo Terzolo***

Full Professor of Internal Medicine  
Head of Division "Internal Medicine"

Director "Department of Clinical and Biological Sciences"  
San Luigi Hospital - University of Turin  
Regione Gonzole, 10  
10043 Orbassano-TO

**PERSONAL DETAILS**

BORN in: Nationality:	TORINO the 25/10/1960 Italian
Phone numbers:	+39 0116705457
E-mail:	<a href="mailto:massimo.terzolo@unito.it">massimo.terzolo@unito.it</a>
Website:	<a href="http://www.dscb.unito.it">www.dscb.unito.it</a>
ORCID ID:	0000-0002-4171-2851
Scopus ID:	7006870178

**EDUCATIONS**

Degree:	MD Degree in Medicine and Surgery
Postgraduate Specialization:	Specialization in Endocrinology

**PROFESSIONAL EXPERIENCES AND CURRENT POSITION**

<p>Assistant Physician at the Division of Internal Medicine of the University Hospital San Luigi Gonzaga, from 1991 to 2001. Head of the Endocrine Laboratory of the Division of Internal Medicine from 2002 to 2009. Associate Professor of Internal Medicine at the University of Turin from 2001 to 2016. Full Professor of Internal Medicine at the Department of Clinical and Biological Sciences, University of Turin since 1 December 2016. Head of the Division of Internal Medicine at the University Hospital San Luigi Gonzaga since 2009. Director of the Department of Clinical and Biological Sciences, University of Turin since 2019.</p>
---

## **PARTICIPATION TO DIRECTIVE BOARDS OF SCIENTIFIC SOCIETIES AND/OR INSTITUTION**

Coordinator of the Expert Panel of the Position Statement on Adrenal Incidentaloma of the Associazione Medici Endocrinologi (AME), published in 2011 (EJE 164: 851-70, 2011).  
Member of the Executive Committee of the "European Network for the Study of Adrenal Tumors – ENS@T" from 2009 to 2014 and Head of the ENS@T NAPACA working group from 2011 to 2017.  
Member of the Expert Panel of the ESE-ENSAT Clinical Guidelines on Adrenal Incidentaloma Management, published in 2016 (EJE 175 (2): G1 -G34).  
Co-Chair of the Expert Panel of the ESE-ENSAT Clinical Guidelines on Adrenal Carcinoma Management, published in 2018 (EJE 179 (4): G1-G46).  
Member of the Endocrine Society, European Society of Endocrinology, European Network for the Study of Adrenal Tumors, Società Italiana di Endocrinologia, Associazione Medici Endocrinologi, Società Italiana di Medicina Interna.

Senior Editor of "Endocrine Connections" since 2017.  
Member of the Editorial Board of "The Journal of Clinical Endocrinology and Metabolism" from 2004 to 2009 and from 2015 to 2019.  
Member of the Editorial Board of "Clinical Endocrinology" since 2009.  
Member of Reviewing Committees of the following journals: Endocrine-Related Cancer, European Journal of Endocrinology, Clinical Endocrinology, Endocrine, The Journal of Endocrinological Investigation.

## **HONORS**

The Endocrine Society and Pharmacia Corporation International Award for Excellence in Published Clinical Research in The Journal of Clinical Endocrinology and Metabolism in 2002 for the paper entitled "Adrenal incidentaloma: a new cause of the metabolic syndrome?" in 2003.  
The Endocrine Society International Award for Publishing Excellence in The Journal of Clinical Endocrinology and Metabolism in 2011 for the paper entitled "Urine steroid metabolomics as a biomarker tool for detecting malignancy in adrenal tumors" in 2012.  
Outstanding Reviewer for the Journal of Clinical Endocrinology and Metabolism in 2005.

## **TEACHING ACTIVITY**

Teacher in the Course of Master's Degree in Medicine and Surgery  
Teacher in the Postgraduate Specialization School of Internal Medicine, Respiratory diseases, thoracic surgery.

## **RESEARCH MAIN TOPICS**

His main research areas are: i) the study of novel diagnostic, prognostic and therapeutic approaches for adrenal cancer patients; ii) the study of peculiar pathophysiologic and clinical features of adrenal tumors; iii) the study of peculiar pathophysiologic and clinical features of Cushing's syndrome; iv) the study of the systemic effects of GH and IGF-I in acromegaly.  
The first project includes the evaluation of new diagnostic techniques, assessment of prognostic factors and development of advanced therapeutic modalities for adrenal cancer.  
The second project includes the characterization of incidentally discovered adrenal masses, the definition of diagnostic aspects of subclinical Cushing's syndrome, the assessment of its clinical impact and the development of new treatment strategies.  
The third project concerns the study of atypical variants of Cushing's syndrome, the efficacy of specific diagnostic tests, and the

assessment of the systemic effects of cortisol excess.

The fourth project concerns the assessment of the clinical consequences of GH and IGF-I excess with particular focus on the relationship between the GH-IGF axis and the neoplastic risk in acromegalic patients.

**Main Project as PI:**

European Coordinator of the academic, international, multicentric randomized study "First International Randomized Trial in locally advanced and Metastatic Adrenocortical Carcinoma – FIRMACT" from 2004 to 2010.

Study Chair of the academic, international, multicentric randomized study "Efficacy of Adjuvant Mitotane Treatment in Prolonging Recurrence-Free Survival in Patients with Adrenocortical Carcinoma at Low-Intermediate Risk of Recurrence - ADIUVO".

Study Chair of the academic, multicentric, prospective study "Efficacy of Abiraterone in patients with Cushing's Syndrome due to Adrenocortical Carcinoma -ABACUS".

European Coordinator of the academic, international, multicentric randomized study "A randomized registry trial of adjuvant mitotane vs. mitotane with cisplatin/ etoposide after primary surgical resection of localized adrenocortical carcinoma with high risk of recurrence -ADIUVO-2".

**Major Scientific Accomplishments In The Research Field:**

Publication of the paper "Adjuvant mitotane treatment for adrenocortical carcinoma." (M.Terzolo, A. Angeli, M. Fassnacht et al., New England Journal of Medicine, 2007; 356: 2372-80). Although retrospective in nature, the study provided the best evidence currently available on the benefit of adjuvant mitotane therapy following radical surgery due to the large patient cohorts and availability of careful matched control groups of untreated patients. The paper is considered a seminal publication that established adjuvant mitotane therapy in the management of patients with adrenocortical carcinoma.

Publication of the paper "Combination chemotherapy in advanced adrenocortical carcinoma." (M. Fassnacht, M. Terzolo, B. Allolio et al., New England Journal of Medicine, 2012; 366: 2189-97). The paper reported the results of the first randomized controlled trial ever done in adrenocortical carcinoma establishing the chemotherapy regimen etoposide, doxorubicin and cisplatin plus mitotane as the standard of treatment for advanced adrenocortical carcinoma.

Coordination of the first randomized controlled trial in adjuvant setting for adrenocortical carcinoma (ADIUVO study) that was funded by the European Union within the FP-7 program ENS@T CANCER consortium. The study has enrolled patients in different European Countries and in Canada with the aim to compare the results of adjuvant mitotane therapy versus no treatment in patients at low risk of recurrence following removal of adrenocortical carcinoma. Enrollment is closed and statistical analysis is under way. The study will provide important evidence-based information on the management of patients with adrenocortical carcinoma.

Co-Chair of the ESE-ENSAT Clinical Guidelines on Adrenal Carcinoma Management. These are the first guidelines published on the topic to provide guidance for health care practitioners.

**BIBLIOMETRY ([www.scopus.com](http://www.scopus.com))**

h-index: 62  
documents: 281  
citations: 15434

**PUBLICATIONS:** author of more than 200 papers on peer-reviewed journals.

Aprile 2023

